PPIB and neoplasm: We demonstrated that NV651 was a more potent cyclophilin inhibitor than CsA or SfA for inhibiting the PPIase activity of several cyclophilins; additionally, it exhibited a higher anti-proliferative capacity than sorafenib and displayed a capacity to decrease tumour growth in vivo.